Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jul;10(Suppl 18):S2138-S2143.
doi: 10.21037/jtd.2018.06.142.

(J)ALEX the great: a new era in the world of ALK inhibitors

Solenn Brosseau  1   2 , Valérie Gounant  1 , Gérard Zalcman  1   2
Affiliations
Editorial

(J)ALEX the great: a new era in the world of ALK inhibitors

Solenn Brosseau et al. J Thorac Dis. 2018 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. G. Zalcman and V. Gounant reported personal fees and non-financial support from ROCHE and PFIZER. Dr. S. Brosseau has no relationships that present a potential conflict of interest to disclose.

Comment on

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed
    1. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661-70. 10.2353/ajpath.2009.080755 - DOI - PMC - PubMed
    1. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971-6. 10.1158/0008-5472.CAN-07-6158 - DOI - PubMed
    1. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12. 10.1016/S1470-2045(11)70232-7 - DOI - PMC - PubMed
    1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9. 10.1016/S1470-2045(12)70344-3 - DOI - PMC - PubMed

LinkOut - more resources